The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions

Molecular Endocrinology

Volumn 13, Issue 10, 1999, Pages 1672-1685

  Webb, Paul ^a   Nguyen, Phuong ^a   Valentine, Cathleen ^a   Lopez, Gabriela N ^a   Kwok, Grace R ^a   McInerney, Eileen ^b   Katzenellenbogen, Benita S ^b   Enmark, Eva ^d   Gustafsson, Jan Åke ^d   Nilsson, Stefan ^c   Kushner, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Karo Bio   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; GENE DELETION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0033305431     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.10.0357     Document Type: Article

References (76)

1. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
2. Editorial: A new actor in the estrogen receptor drama - Enter ER β
3. Estrogen receptor β: Re-evaluation of estrogen and antiestrogen signaling
4. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
5. The nuclear hormone receptor gene superfamily
6. Estrogen receptors: Bioactivities and interactions with cell signaling pathways
7. Nuclear receptor coactivators and core-pressors
8. Nuclear receptor coactivators
9. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex
10. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis
11. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
12. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
13. Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites
14. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells
15. Identification of an estrogen response element activated by metabolites of 17-β-estradiol and raloxifene
16. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence
17. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β
18. The novel estrogen-responsive B-box protein (EBBP) gene is tamoxifen-regulated in cells expressing an estrogen receptor DNA-binding domain mutant
19. Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: Role of estrogen receptor-Sp1 interactions
20. Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter
21. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
22. Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras
23. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex
24. Mechanisms of antihormone action
25. Steroid and related receptors
26. The human estrogen receptor has two independent nonacidic transcriptional activation functions
27. Identification of constitutive and steroid-dependent transactivation domains in the mouse oestrogen receptor
28. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β
29. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
30. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors
31. Molecular basis of agonism and antagonism in the oestrogen receptor
32. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
33. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding dependent and independent pathways
34. The transcriptional coactivator p/ClP binds CBP and mediates nuclear-receptor function
35. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
36. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities
37. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor
38. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1
39. Structure and specificity of nuclear receptor-coactivator interactions
40. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
41. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
42. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
43. The nuclear corepressors N-CoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor
44. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor
45. SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors
46. AF-2-dependent potentiation of CCAAT enhancer binding protein β-mediated transcriptional activation by glucocorticoid receptor
47. The N-terminal transactivation domain of rat estrogen receptor is localized in a hydrophobic domain of eighty amino acids
48. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors
49. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells
50. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation
51. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region
52. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity
53. Characterization of ligand-dependent phosphorylation of the estrogen receptor
54. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
55. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
56. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex
57. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
58. The novel estrogen receptor-β subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens
59. Cloning and characterization of human estrogen receptor β isoforms
60. The complete primary structure of human estrogen receptor β (hER β) and its heterodimerization with ER α in vivo and in vitro
61. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors
62. Identification of a novel cis-acting element in the promoter of an estrogen-responsive gene that modulates sensitivity to hormone and antihormone
63. Estrogen receptor β activates the human retinoic acid receptor α-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen
64. Functional analysis of a novel estrogen receptor-β isoform
65. Co-activators and co-repressors in the integration of transcriptional responses
66. Examination of the DNA-binding ability of estrogen receptor in whole cells: Implications for hormone-independent transactivation and the actions of antiestrogens
67. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
68. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
69. Clinical potential of new antiestrogens
70. Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow
71. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity
72. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
73. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia
74. Functional domains of the human estrogen receptor
75. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties
76. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein